Navigation Links
Caliper Life Sciences Launches IVIS(R) In Vivo Imaging System with X-Ray
Date:9/14/2009

HOPKINTON, Mass., Sept. 14 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP), a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family. The Lumina XR system combines highly sensitive bioluminescence and fluorescence molecular optical imaging with the anatomical precision of digital x-ray. Integrating these three imaging modalities provides researchers with additional capabilities to explore the molecular basis of disease and determine the response to drug therapies.

Caliper's non-invasive IVIS preclinical molecular optical imaging technology is an innovative research tool that has greatly advanced both basic scientific research as well as the novel breakthrough research necessary to develop safe new drugs. To date, peer-reviewed publications show that IVIS technology has aided the discovery and development of five FDA-approved therapies and more than nine drug compounds in development. The introduction of the Lumina XR system takes this innovation one step further by combining optical fluorescent and bioluminescent images of biological activity with co-registered digital x-ray images, enhancing the anatomical context of the optical molecular signals. For example, with x-ray co-registration the researcher can view a detailed image of the skeleton, or even certain soft tissues, and can use those images as a reference point when using bioluminescence to more precisely locate a tumor or infection site in an animal.

"Caliper's bioluminescent and fluorescent IVIS imaging systems are well recognized by researchers at top universities and pharmaceutical companies as the leading pre-clinical in vivo imaging solution," sai
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Caliper Life Sciences Reports Second Quarter 2009 Results
2. Caliper Life Sciences Second Quarter 2009 Financial Results Conference Call Notice
3. Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation & Analysis
4. Caliper Life Sciences to Webcast Investor Session of Open House
5. Caliper Life Sciences Reports First Quarter 2009 Results
6. Caliper Life Sciences Announces Date and Location of its 2009 Annual Meeting of Stockholders
7. EPA Presents Initial Results from Caliper Life Sciences ToxCast Screening Effort
8. Caliper Life Sciences Reports Fourth Quarter and Full Year 2008 Results
9. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
10. Caliper Life Sciences Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
11. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/...vator in biotechnology for diabetes therapy, and a...ervices to food, supplement, biotechnology and pha...he previously reported $6.3 million registered dir...870 shares of its common stock and warrants to pur...
(Date:11/19/2009)...VERN, Pa. and WALTHAM, Mass., Nov. 19 /PRNewswire/... Resources find that the leading driver of antibio... broad-spectrum activity against gram-positive and...ganisms that can cause nosocomial pneumonia, surve...arily for agents that provide appropriate coverage...
(Date:11/19/2009)... Top LASIK surgeons and recognized refracti...LASIK Surgeons made brought their fellow surgeons ...rrection surgery, cataract surgery, and ophthalmol...Academy of Ophthalmology (AAO) annual meeting in S...r. Shachar Tauber, Dr. David Huang, MD, Dr. Randy ...
(Date:11/19/2009)... VIENNA, Austria, November 19 AFFi...on one product candidate at an unexpectedly early,...s planned to enter into,Phase II clinical trial ea...ely follows the completion of two Phase I trials w...d its fast decision on the first interim,analysis ...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3
...on Will be Webcast Live and Archived on Company,s ...cals,Inc. (Nasdaq: VNDA ), a biopharmaceutical co...tion of clinical-stage product candidates for cent... the company will deliver a,corporate presentation...me., The presentation will take place as part of ...
... May 8 /PRNewswire-FirstCall/ - Angiotech Pharmace...specialty pharmaceutical and,medical device compan...ica,2008 Health Care Conference, which is being he...nter, Angiotech,s President and Chief Executive Of..., beginning at approximately,4:00 pm Pacific Time....
..., May 8 Applied Isotope Technologies ("AIT"),anno...Discovery Products,will be exclusively used for th...etabolic biochemical assessment when they are plac...ucted at The Children,s Institute,in Pittsburgh, P...m,Disorders (ASD) will lead a team of scientists f...
Other Biology Technology:Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Applied Isotope Technologies will Exclusively Supply Biochemimarker(TM) Discovery Products for a Unique Pilot Study on Autism 2
(Date:11/19/2009)... This week, scientists are revealing the genetic ...eal crops. Corn, or maize, has one of the most com...ty of Wisconsin-Madison genomicist David Schwartz,...le in the journal Science . , "The maize genome...d-ends that have troubled would-be sequencers for ...
(Date:11/19/2009)... comes to corn, 1 + 1 = more than 2: The offspring... of their parents. Characterizing the gene-level v... heterosis or hybrid vigor, could boost our abilit... as high protein content for human consumption or ...elp from the newly released DNA sequence of the co...
(Date:11/19/2009)...ssive survey of genetic diversity in maize, also k..., have developed a gene map that should pave the w...a major source of food, fuel, animal feed and fibe...e of gene map known as a haplotype map, charts gen... of 27 inbred lines of maize. The research team, l...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2JCI table of contents 3A Oct 19 2009 59769 1JCI table of contents 3A Oct 19 2009 59769 2JCI table of contents 3A Oct 19 2009 59769 3Research with wood ducks earns graduate student 2 national awards 10420 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 1Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 2Vasogen Inc and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger 14530 3
...n Australia have discovered that cane toads are fa...at ants than native frogs. Their research publish...nctional Ecology reveals a chink in the cane toa...his alien invasive species in tropical Australia. ... Ward-Fear, Matt Greenlees and Greg Brown from the...
...ch 30, 2009 In an international human genetic stu...have identified a gene linked to the autoimmune di...might help explain why females are 10 times more s...ng this gene, IRAK1, as a disease gene may also ha...n, professor of internal medicine and senior autho...
... to animals of omega 3 fatty acids in fish oils ha...culatory system, improving meat quality and reduci...ay only apply to cows but lowering emissions is im...by farm animals is a major contribution to greenho...s from University College Dublin reported that by ...
Other Biology News:Aussie meat ants may be invasive cane toad's Achilles' heel 2Gene linked to lupus might explain gender difference in disease risk 2
Rabbit Anti-Human Rad51 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human Sirtuin (silent mating type information regulation 2, S.cerevisiae, homolog) 7 (SIRT7) Polyclonal Antibody, Unconjugated from Lifespan Biosciences
...r RNA aptamer screening and binding optimization a...ofluidic on-chip synthesis platform. These microar...A/RNA Aptamer Microarray Service. Probe Content ...s greater than 1500 known aptamer sequences. Add u...
Biology Products: